利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.026 秒)

    Acute hepatic insufficiency depressant and method for evaluating drug efficacy thereof
    1.
    发明授权
    Acute hepatic insufficiency depressant and method for evaluating drug efficacy thereof 有权
    急性肝功能不全抑制剂及其药效的评价方法

    公开(公告)号：US09272018B2

    公开(公告)日：2016-03-01

    申请号：US14112490

    申请日：2012-04-18

    申请人： Hirohito Tsubouchi ,  Akio Ido ,  Tsutomu Chiba ,  Akira Shimizu

    发明人： Hirohito Tsubouchi ,  Akio Ido ,  Tsutomu Chiba ,  Akira Shimizu

    IPC分类号： A61K38/18 ,  C07K14/475 ,  A61K39/395 ,  G01N33/68

    CPC分类号： A61K38/1833 ,  A61K39/3955 ,  C07K14/4753 ,  G01N33/6893 ,  G01N2800/085 ,  G01N2800/52

    摘要： The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of α-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.

    摘要翻译： 本发明提供了含有肝细胞生长因子（HGF）的急性肝衰竭治疗剂，特别是用于治疗暴发性肝炎或迟发性肝衰竭或抑制急性肝衰竭进展的药物，没有肝昏迷至暴发性肝炎或晚发性肝脏 失败。 本发明还提供一种用于评估HGF功效的方法，包括测量从施用HGF的肝损伤患者获得的样品中甲胎蛋白（肝脏再生生物标志物）和/或可溶性Fas（抗凋亡生物标志物）的量。

    ACUTE HEPATIC INSUFFICIENCY DEPRESSANT AND METHOD FOR EVALUATING DRUG EFFICACY THEREOF
    2.
    发明申请
    ACUTE HEPATIC INSUFFICIENCY DEPRESSANT AND METHOD FOR EVALUATING DRUG EFFICACY THEREOF 有权
    急性肝功能衰竭及评估药物效果的方法

    公开(公告)号：US20140234341A1

    公开(公告)日：2014-08-21

    申请号：US14112490

    申请日：2012-04-18

    申请人： Hirohito Tsubouchi ,  Akio Ido ,  Tsutomu Chiba ,  Akira Shimizu

    发明人： Hirohito Tsubouchi ,  Akio Ido ,  Tsutomu Chiba ,  Akira Shimizu

    IPC分类号： A61K38/18 ,  A61K39/395 ,  G01N33/68

    CPC分类号： A61K38/1833 ,  A61K39/3955 ,  C07K14/4753 ,  G01N33/6893 ,  G01N2800/085 ,  G01N2800/52

    摘要： The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of α-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.

    摘要翻译： 本发明提供了含有肝细胞生长因子（HGF）的急性肝衰竭治疗剂，特别是用于治疗暴发性肝炎或迟发性肝衰竭或抑制急性肝衰竭进展的药物，没有肝昏迷至暴发性肝炎或晚发性肝脏 失败。 本发明还提供一种用于评估HGF功效的方法，包括测量从施用HGF的肝损伤患者获得的样品中甲胎蛋白（肝脏再生生物标志物）和/或可溶性Fas（抗凋亡生物标志物）的量。

    Agent for inhibiting production of hepatitis C virus and its use
    3.
    发明授权
    Agent for inhibiting production of hepatitis C virus and its use 有权
    用于抑制丙型肝炎病毒生产的药剂及其用途

    公开(公告)号：US08846751B2

    公开(公告)日：2014-09-30

    申请号：US13204219

    申请日：2011-08-05

    申请人： Masahiko Takeshita ,  Hirohito Tsubouchi ,  Hirofumi Uto ,  Hiroaki Kataoka ,  Takanori Kai ,  Hideaki Hirabaru ,  Miho Sakai ,  Ena Akamatsu

    发明人： Masahiko Takeshita ,  Hirohito Tsubouchi ,  Hirofumi Uto ,  Hiroaki Kataoka ,  Takanori Kai ,  Hideaki Hirabaru ,  Miho Sakai ,  Ena Akamatsu

    IPC分类号： A01N43/16 ,  C07D311/62 ,  A61K31/74 ,  A61K36/45

    CPC分类号： A61K31/74 ,  A61K36/45 ,  C07D311/62

    摘要： This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1), wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer composition said units of flavan-3-ol being bonded each other in any one of three patterns as follows; (i) a bond between carbon at the position 4 and carbon at the position 8, (ii) a bond between carbon at the position 4 and carbon at the position 6, (iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon, at the position 2 and oxygen at the position 7.

    摘要翻译： 本发明提供用于抑制具有显着的抗HCV活性并且没有副作用的丙型肝炎病毒生产的药剂。 该试剂包含如下通式（1）所示的原花青素聚合物组合物，其中R 1为氢或羟基，R 2为羟基，R 3为氢时，R 1为氢或羟基，但当R 1为氢时，R 3为羟基 或羟基，其中R 1和R 3为羟基在原花色素聚合物组合物中至多为40％的程度，所述黄烷-3-醇单元以如下三种模式中的任一种彼此结合; （i）位置4的碳和位置8的碳之间的键，（ii）位置4的碳与位置6的碳之间的键;（iii）位置4的碳与碳之间的键 位置8，碳之间，位置2和位置7处的氧。

    Biomarker for diagnosis of liver disease
    6.
    发明授权
    Biomarker for diagnosis of liver disease 失效
    用于肝脏疾病诊断的生物标志物

    公开(公告)号：US08263347B2

    公开(公告)日：2012-09-11

    申请号：US12738684

    申请日：2008-10-20

    申请人： Hirohito Tsubouchi ,  Hirofumi Uto ,  Takeshi Okanoue ,  Yo-ichi Ishida ,  Yuko Sato ,  Masayuki Sudo

    发明人： Hirohito Tsubouchi ,  Hirofumi Uto ,  Takeshi Okanoue ,  Yo-ichi Ishida ,  Yuko Sato ,  Masayuki Sudo

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6893 ,  G01N2333/8139 ,  G01N2800/085

    摘要： Disclosed are: a marker for the diagnosis of a liver disease, which can determine the disease in a simple manner; an antibody directed against the marker; a diagnostic agent; a diagnosis method; and a method for marker detection in blood or serum. Proteome analysis revealed that quantities of the full-length kininogen and three partial peptides thereof (sequence A: position-440 to position-456, sequence B: position-439 to position-456, and sequence C: position-438 to position-456) in sera of patients with non-alcoholic fatty liver disease are significantly different from those in sera of healthy individuals; and a diagnostic agent and a detecting method for the non-alcoholic fatty liver disease that can be conveniently used for medical examination are established. The use of a combination of a kininogen-based marker and a C4-based marker (the full length sequence or partial peptides thereof) enables identification of chronic hepatitis and an asymptomatic virus carrier, as well as non-alcoholic fatty liver disease.

    摘要翻译： 公开了一种用于诊断肝脏疾病的标志物，其可以以简单的方式确定疾病; 针对标记的抗体; 诊断剂; 诊断方法; 以及血液或血清中标记物检测的方法。 蛋白质组分析显示，全长激肽原及其三个部分肽（序列A：位置440至位置-456，序列B：位置-439至位置-456，序列C：位置-438至位置-456） ）与非酒精性脂肪性肝病患者的血清显着不同于健康人血清; 并建立了可以方便地用于体格检查的非酒精性脂肪肝疾病的诊断剂和检测方法。 使用基于激肽原的标记物和基于C4的标记物（其全长序列或其部分肽）的组合能够鉴定慢性肝炎和无症状病毒载体以及非酒精性脂肪肝疾病。

    BIOMARKER FOR DIAGNOSIS OF LIVER DISEASE
    7.
    发明申请
    BIOMARKER FOR DIAGNOSIS OF LIVER DISEASE 失效
    生物标志物诊断肝病

    公开(公告)号：US20110129859A1

    公开(公告)日：2011-06-02

    申请号：US12738684

    申请日：2008-10-20

    申请人： Hirohito Tsubouchi ,  Hirofumi Uto ,  Takeshi Okanoue ,  Yo-ichi Ishida ,  Yuko Sato ,  Masayuki Sudo

    发明人： Hirohito Tsubouchi ,  Hirofumi Uto ,  Takeshi Okanoue ,  Yo-ichi Ishida ,  Yuko Sato ,  Masayuki Sudo

    IPC分类号： G01N33/53 ,  C07K7/08 ,  C07K14/435 ,  C07K16/18

    CPC分类号： G01N33/6893 ,  G01N2333/8139 ,  G01N2800/085

    摘要： Disclosed are: a marker for the diagnosis of a liver disease, which can determine the disease in a simple manner; an antibody directed against the marker; a diagnostic agent; a diagnosis method; and a method for marker detection in blood or serum. Proteome analysis revealed that quantities of the full-length kininogen and three partial peptides thereof (sequence A: position-440 to position-456, sequence B: position-439 to position-456, and sequence C: position-438 to position-456) in sera of patients with non-alcoholic fatty liver disease are significantly different from those in sera of healthy individuals; and a diagnostic agent and a detecting method for the non-alcoholic fatty liver disease that can be conveniently used for medical examination are established. The use of a combination of a kininogen-based marker and a C4-based marker (the full length sequence or partial peptides thereof) enables identification of chronic hepatitis and an asymptomatic virus carrier, as well as non-alcoholic fatty liver disease.

    摘要翻译： 公开了：用于诊断肝脏疾病的标志物，其可以以简单的方式确定疾病; 针对标记的抗体; 诊断剂; 诊断方法; 以及血液或血清中标记物检测的方法。 蛋白质组分析显示，全长激肽原及其三个部分肽（序列A：位置440至位置-456，序列B：位置-439至位置-456，序列C：位置-438至位置-456） ）与非酒精性脂肪性肝病患者的血清显着不同于健康人血清; 建立了可以方便地用于体格检查的非酒精性脂肪肝疾病的诊断剂和检测方法。 使用基于激肽原的标记物和基于C4的标记物（其全长序列或其部分肽）的组合能够鉴定慢性肝炎和无症状病毒载体以及非酒精性脂肪肝疾病。

    Method of preventing or treating liver disease
    8.
    发明申请
    Method of preventing or treating liver disease 审中-公开
    预防或治疗肝病的方法

    公开(公告)号：US20060094679A1

    公开(公告)日：2006-05-04

    申请号：US11208544

    申请日：2005-08-23

    申请人： Hirohito Tsubouchi ,  Satoru Hasuike

    发明人： Hirohito Tsubouchi ,  Satoru Hasuike

    IPC分类号： A61K48/00 ,  A61K38/17

    CPC分类号： A61K38/1709 ,  A61K48/00 ,  C07K14/575

    摘要： An object of the present invention is to provide a method of preventing or treating liver disease, particularly non-alcoholic fatty liver disease, hepatic fibrosis, cirrhosis, or liver cancer. The present invention is directed to a method of preventing or treating liver disease comprising administering to a patient in need thereof an effective amount of an osteoactivin-like protein or a fragment thereof having liver disease-suppressing activity similar to that of osteoactivin or a gene comprising a DNA encoding such a protein or fragment.

    摘要翻译： 本发明的目的是提供一种预防或治疗肝病，特别是非酒精性脂肪肝疾病，肝纤维化，肝硬化或肝癌的方法。 本发明涉及一种预防或治疗肝脏疾病的方法，包括向有需要的患者施用有效量的具有类似于骨质疏植蛋白的肝脏疾病抑制活性的类骨质疏松素样蛋白或其片段或包含 编码这种蛋白质或片段的DNA。